Forest Laboratories, Inc. (NYSE: FRX) announced that study results show Lexapro (escitalopram oxalate) significantly improved symptoms of depression as compared to placebo treatment and was well tolerated in adolescents, aged 12-17, with major depressive disorder (MDD), according to phase III data presented at the 2008 Annual Meeting of the American Psychiatric Association.
Popularity: unranked [?]
Related posts:
- Deep Brain Stimulation For Depression Pilot Study Demonstrates Sustained Improvement In Depression Symptoms
- Seroquel Evaluation On Improvement In Short And Long-Term Symptoms
- Patients In St. Jude Medical Deep Brain Stimulation For Depression Pilot Study Demonstrate Sustained Improvement In Depression Symptoms
- Ridge Diagnostics, Inc. Clinical Data On Blood Test For Depression Presented At American Psychiatric Association Annual Meeting
- Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement In Symptoms Of Depression In Adult Patients Versus Placebo
Comments
No Responses to “Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms In Adolescents”